Figuring out how to know if you qualify for MAT is often the question that stands between someone and a treatment that actually works. The answer is more accessible than most people expect, and the bar for eligibility is set by clinical need, not by how “bad enough” your situation looks from the outside.
What MAT Actually Is
Medication-assisted treatment combines FDA-approved medications with counseling to treat opioid use disorder and alcohol use disorder. The three primary medications are methadone, buprenorphine, and naltrexone. Each works differently, but all three reduce cravings, stabilize brain chemistry disrupted by addiction, and give the counseling component room to actually work.
According to SAMHSA’s 2023 National Survey on Drug Use and Health, fewer than 20% of people with opioid use disorder receive any treatment at all. That gap exists partly because of access barriers and partly because people don’t know whether they qualify. The most persistent misconception is that MAT means swapping one drug for another. It doesn’t. These medications are prescribed at therapeutic doses to treat a medical condition, the same way insulin treats diabetes. Dismissing MAT on those grounds is the equivalent of refusing blood pressure medication because it “still involves taking something.”
The Substances MAT Is Designed to Treat
MAT has the strongest clinical evidence base for opioid use disorder, covering heroin, prescription painkillers like oxycodone and hydrocodone, and illicit fentanyl. It’s also a recognized treatment for alcohol use disorder, where naltrexone and acamprosate reduce relapse rates significantly. Some protocols address polysubstance use, particularly when opioids are part of the picture.
A 2023 NIDA report on treatment outcomes found that MAT for opioid use disorder reduces illicit drug use, criminal activity, and overdose mortality, with retention rates substantially higher than behavioral treatment alone. The practical takeaway is straightforward: if the substance you use appears on this list, that alone is a strong clinical signal to pursue a formal evaluation. You don’t need certainty. You need an appointment.
Core Eligibility Criteria for MAT
Eligibility for MAT isn’t determined by a single cutoff. Clinicians use a combination of diagnostic criteria, history, and health factors to assess whether MAT is appropriate and which medication fits best.
A Diagnosed or Diagnosable Substance Use Disorder
The clinical baseline is a substance use disorder diagnosis, assessed using the DSM-5 criteria. There are 11 criteria total, covering things like loss of control over use, continued use despite consequences, tolerance, and withdrawal. Meeting two or more qualifies as a diagnosable SUD, with severity determined by how many criteria apply.
One thing worth knowing: you don’t walk in needing a prior diagnosis. A licensed clinician conducts the assessment at intake. If you’ve never been formally evaluated, that assessment is the first step, not a prerequisite. Understanding what that first evaluation actually involves can make the process feel less daunting before you walk in.
History of Dependence, Tolerance, or Failed Attempts to Stop
Physical dependence, withdrawal symptoms, and prior treatment attempts all factor into eligibility. According to 2022 NIDA data, relapse rates for opioid use disorder run between 40% and 60%. That statistic exists not to discourage, but to establish the clinical reality: relapse is part of the disorder’s course, not evidence of personal failure.
A history of relapse strengthens the case for MAT. It demonstrates the kind of neurological grip that behavioral intervention alone hasn’t been able to break. Providers see prior attempts as clinical data, not as a record of failure.
Length and Severity of Use
Duration and pattern of use matter. Daily use, escalating doses, and the inability to control use despite repeated attempts to cut back are the patterns clinicians look for. Providers typically use standardized screening tools: the AUDIT (Alcohol Use Disorders Identification Test) for alcohol and the DAST (Drug Abuse Screening Test) for substances more broadly.
Before your evaluation, write down how long you’ve been using, what you use, and an honest estimate of how much. That information is exactly what a provider needs to complete an accurate assessment, and having it ready shortens the intake conversation significantly.
Medical and Health Factors That Affect Eligibility
Co-occurring physical health conditions shape which MAT medication is appropriate, not whether MAT is appropriate. Liver function is relevant when considering certain medications, since some are metabolized hepatically and require dosage consideration. Chronic pain is another factor, since opioid dependence and pain management sometimes overlap in ways that inform the treatment plan.
Pregnancy is worth addressing directly. The American College of Obstetricians and Gynecologists (ACOG) 2023 guidelines identify buprenorphine and methadone as the standard of care for opioid use disorder during pregnancy. MAT during pregnancy is not a risk to weigh against sobriety. It is the recommended clinical path. Neonatal opioid withdrawal syndrome is manageable, and outcomes for both mother and child are consistently better when the mother receives MAT than when she attempts abstinence unsupported.
Mental Health and Co-Occurring Conditions
A 2022 JAMA Psychiatry analysis found that approximately 50% of people with opioid use disorder have at least one co-occurring mental health condition, most commonly depression, anxiety, or PTSD. Co-occurring disorders are the norm, not the exception.
These conditions don’t disqualify someone from MAT. They inform the treatment plan. A clinician who knows your full mental health history from the start builds a plan that addresses both conditions simultaneously, rather than treating one and missing the other. At intake, disclose all mental health history, including diagnoses, current medications, and any trauma background. Withholding that information doesn’t protect you; it limits the quality of care you receive.
Who Qualifies for MAT-Specific Medications
Different medications serve different clinical profiles. Eligibility criteria vary by medication, so understanding the distinctions helps you know what to expect.
Buprenorphine (Suboxone)
Buprenorphine is indicated for opioid dependence and is prescribed in office-based settings, including via telehealth across Pennsylvania. A significant regulatory shift in 2023 eliminated the federal waiver requirement that had previously restricted which providers could prescribe it, which meaningfully expanded access. Buprenorphine can be initiated without requiring full detox first. Telehealth prescribing means you can begin the eligibility conversation from home, which removes one of the most common access barriers. If you’re curious about how to access buprenorphine for the first time, that process is more straightforward than most people assume.
Methadone
Methadone is dispensed through federally regulated opioid treatment programs (OTPs), which operate as dedicated clinics with daily dispensing requirements, especially in early treatment. Eligibility typically requires at least one year of documented opioid dependence. Methadone is often the preferred option for people with severe, long-standing opioid use disorder, or when other medications haven’t provided adequate stabilization. The requirement for in-person clinic attendance is a real logistical consideration, but for appropriate candidates, the clinical outcomes justify it.
Naltrexone (Vivitrol)
Naltrexone has no opioid component, which makes it a fundamentally different treatment profile. It works by blocking opioid receptors rather than activating them. The injectable form (Vivitrol) is administered monthly. The catch is that full detox must be completed before starting, since any opioids remaining in the system will trigger precipitated withdrawal. A 2023 VA-funded study on injectable naltrexone found significant reductions in opioid relapse in veterans with OUD who completed detox. Naltrexone is also effective for alcohol use disorder, making it a strong option when alcohol is the primary or co-primary concern.
Special Populations Who Qualify
Pregnant and Postpartum Women
The ACOG position is unambiguous: MAT with buprenorphine or methadone is the recommended standard of care for pregnant women with opioid use disorder. If you’re pregnant and using opioids, a MAT evaluation is the first clinical step, not a last resort. Neonatal opioid withdrawal syndrome is a known and manageable outcome that neonatal teams have established protocols to treat. Untreated opioid use disorder during pregnancy carries far greater risk.
Working Professionals
The concern that entering MAT means disrupting employment is real but largely solvable. Office-based buprenorphine and telehealth prescribing in Pennsylvania allow treatment to happen on a schedule that doesn’t require visible time away. FMLA protections apply to substance use disorder treatment, though most patients using telehealth and outpatient MAT never need to invoke them. At intake, ask specifically about telehealth options and appointment scheduling.
People Who Have Relapsed Before
The 2023 Surgeon General’s advisory on addiction explicitly frames opioid use disorder as a chronic brain disorder with expected cycles of remission and relapse. That framing matters clinically. Relapse is a data point about the nature of the condition, not a judgment about the person experiencing it. Taking the first steps toward help after a relapse is not starting over from zero; it’s continuing treatment for a chronic condition that requires ongoing management.
Common Reasons People Think They Don’t Qualify (And Why They’re Wrong)
“I’m not using enough.” There’s no minimum quantity threshold for MAT eligibility. The DSM-5 criteria measure behavioral and functional impact, not dosage. If use is causing problems, that’s the relevant signal.
“I’ve only been using a short time.” Duration is one factor among many. Early-stage dependence is still dependence, and early treatment consistently produces better outcomes than delayed intervention. Waiting until the problem is worse is not a clinical strategy.
“I already tried MAT and relapsed.” This is among the strongest arguments for continuing MAT, not abandoning it. NIDA’s chronic disease model is explicit: returning to treatment after relapse is appropriate and expected. A prior attempt tells a provider that you understand the process and have the motivation to try again with potentially adjusted medication or support.
“My doctor will judge me.” Providers who specialize in addiction medicine see substance use disorder as a medical condition requiring medical treatment. Shame-based encounters happen, but they’re a failure of that individual provider, not a feature of MAT care. If you’re not sure what questions a clinic typically asks during intake, knowing what to expect in advance removes a significant source of pre-appointment anxiety.
The One Step That Answers the Question
The only way to know definitively whether you qualify for MAT is to speak with a licensed clinician. An intake evaluation typically takes one appointment, often under an hour, and most outpatient MAT providers in Pennsylvania accept major insurance plans. Telehealth options mean that evaluation can happen without leaving your home. Understanding how insurance verification works for addiction treatment before you call removes one of the last logistical barriers people use to delay the conversation.
Call a MAT provider this week and request an intake evaluation. Not a commitment to treatment. An evaluation. That single call answers the eligibility question definitively and puts a clinical opinion in place of the uncertainty that’s been doing the real work of keeping you from starting.
